Claro Advisors LLC Has $732,000 Stake in CVS Health Co. (NYSE:CVS)

Claro Advisors LLC grew its stake in CVS Health Co. (NYSE:CVS) by 12.2% during the first quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 9,172 shares of the pharmacy operator’s stock after purchasing an additional 1,000 shares during the quarter. Claro Advisors LLC’s holdings in CVS Health were worth $732,000 at the end of the most recent reporting period.

Other hedge funds also recently modified their holdings of the company. SOA Wealth Advisors LLC. raised its holdings in shares of CVS Health by 4.9% during the 4th quarter. SOA Wealth Advisors LLC. now owns 2,859 shares of the pharmacy operator’s stock worth $226,000 after acquiring an additional 133 shares in the last quarter. Apella Capital LLC raised its position in shares of CVS Health by 4.2% during the 4th quarter. Apella Capital LLC now owns 3,378 shares of the pharmacy operator’s stock valued at $272,000 after buying an additional 136 shares in the last quarter. Prairie Sky Financial Group LLC grew its position in CVS Health by 4.1% in the fourth quarter. Prairie Sky Financial Group LLC now owns 3,612 shares of the pharmacy operator’s stock worth $285,000 after acquiring an additional 141 shares in the last quarter. WealthShield Partners LLC increased its stake in CVS Health by 3.2% during the fourth quarter. WealthShield Partners LLC now owns 4,498 shares of the pharmacy operator’s stock worth $355,000 after acquiring an additional 141 shares during the last quarter. Finally, Sugarloaf Wealth Management LLC boosted its holdings in shares of CVS Health by 9.5% in the 4th quarter. Sugarloaf Wealth Management LLC now owns 1,639 shares of the pharmacy operator’s stock worth $129,000 after purchasing an additional 142 shares during the period. Hedge funds and other institutional investors own 80.66% of the company’s stock.

Wall Street Analyst Weigh In

Several brokerages have recently weighed in on CVS. Baird R W raised shares of CVS Health to a “hold” rating in a research note on Thursday, May 30th. Cantor Fitzgerald reaffirmed a “neutral” rating and set a $58.00 target price on shares of CVS Health in a research note on Wednesday, June 12th. JPMorgan Chase & Co. decreased their price target on CVS Health from $101.00 to $86.00 and set an “overweight” rating for the company in a research note on Thursday, May 30th. The Goldman Sachs Group reduced their target price on CVS Health from $85.00 to $74.00 and set a “buy” rating on the stock in a research note on Thursday, May 2nd. Finally, Robert W. Baird started coverage on shares of CVS Health in a report on Thursday, May 30th. They issued a “neutral” rating and a $61.00 price target on the stock. Eleven research analysts have rated the stock with a hold rating and thirteen have issued a buy rating to the company. Based on data from MarketBeat.com, CVS Health has an average rating of “Moderate Buy” and an average price target of $75.05.

CVS Health Price Performance

Shares of CVS opened at $58.14 on Tuesday. The firm has a market capitalization of $72.99 billion, a PE ratio of 10.22, a price-to-earnings-growth ratio of 0.56 and a beta of 0.52. The company has a debt-to-equity ratio of 0.78, a current ratio of 0.81 and a quick ratio of 0.61. The company’s fifty day moving average price is $59.56 and its 200-day moving average price is $70.13. CVS Health Co. has a 1-year low of $52.77 and a 1-year high of $83.25.

CVS Health (NYSE:CVS) last posted its quarterly earnings results on Wednesday, May 1st. The pharmacy operator reported $1.31 earnings per share for the quarter, missing the consensus estimate of $1.69 by ($0.38). The firm had revenue of $88.44 billion for the quarter, compared to analysts’ expectations of $89.33 billion. CVS Health had a net margin of 2.03% and a return on equity of 13.53%. The firm’s revenue for the quarter was up 3.7% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $2.20 EPS. On average, equities research analysts predict that CVS Health Co. will post 7.02 EPS for the current year.

Insider Transactions at CVS Health

In other CVS Health news, Director Edward J. Ludwig purchased 1,000 shares of the stock in a transaction on Thursday, May 2nd. The shares were bought at an average cost of $53.88 per share, with a total value of $53,880.00. Following the completion of the acquisition, the director now owns 21,630 shares in the company, valued at $1,165,424.40. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Company insiders own 0.24% of the company’s stock.

About CVS Health

CVS Health Corporation provides health solutions in the United States. It operates through Health Care Benefits, Health Services, and Pharmacy & Consumer Wellness segments. The Health Care Benefits segment offers traditional, voluntary, and consumer-directed health insurance products and related services.